Medigus (NASDAQ:MDGS – Get Rating) and Insulet (NASDAQ:PODD – Get Rating) are both business services companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.
Valuation and Earnings
This table compares Medigus and Insulet’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medigus | $91.86 million | 0.06 | -$9.81 million | N/A | N/A |
| Insulet | $1.31 billion | 15.03 | $4.60 million | N/A | N/A |
Insulet has higher revenue and earnings than Medigus.
Risk and Volatility
Institutional & Insider Ownership
9.2% of Medigus shares are owned by institutional investors. 2.2% of Medigus shares are owned by company insiders. Comparatively, 0.8% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for Medigus and Insulet, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medigus | 0 | 0 | 0 | 0 | N/A |
| Insulet | 0 | 7 | 6 | 0 | 2.46 |
Insulet has a consensus target price of $330.00, suggesting a potential upside of 17.24%. Given Insulet’s higher probable upside, analysts plainly believe Insulet is more favorable than Medigus.
Profitability
This table compares Medigus and Insulet’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medigus | N/A | N/A | N/A |
| Insulet | 0.04% | 17.29% | 3.59% |
Summary
Insulet beats Medigus on 9 of the 11 factors compared between the two stocks.
About Medigus
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, and visualization solutions; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
About Insulet
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Receive News & Ratings for Medigus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigus and related companies with MarketBeat.com's FREE daily email newsletter.
